Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2025-04-23 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
第五届董事会第二十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a specific board meeting of the company, including details about the meeting attendance, agenda items, and voting results. It does not contain financial statements or detailed financial performance data. It is not an annual or interim report, nor an earnings release. It is not a regulatory certification or a report publication announcement. The content focuses on board decisions, specifically about appointing a trustee for convertible bonds and scheduling a bondholders meeting. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2025-04-23 Chinese
关于召开健帆转债2025年第一次债券持有人会议的通知
Capital/Financing Update Classification · 95% confidence The document is a detailed notice about convening the first bondholders' meeting in 2025 for a convertible bond issued by the company. It includes information about the meeting date, voting procedures, registration, and agenda items such as appointing a trustee for the convertible bonds. There is no financial data or results reported, nor is it an announcement of financial results or a report publication. It is not a general shareholder meeting but a bondholders' meeting. The document is a formal meeting notice and related procedural documents for bondholders to vote on bond-related matters. This fits best under the category of Capital/Financing Update (CAP), as it relates to bondholder meetings and decisions affecting the company's convertible bonds and financing instruments.
2025-04-23 Chinese
国浩律师（深圳）事务所关于健帆生物科技集团股份有限公司2022年股票期权激励计划注销部分股票期权之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of certain stock options under a 2022 stock option incentive plan of a company. It details the approval and authorization process, reasons for cancellation, and compliance with relevant laws and regulations. The document is not a financial report, earnings release, or regulatory announcement but a legal opinion related to stock option cancellations. This fits best under the category of Regulatory Filings (RNS) as it is a legal compliance document and does not constitute a financial report or announcement of voting results or capital changes. The document length is sufficient and contains detailed legal analysis, not just a brief announcement or certification.
2025-04-15 Chinese
2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "健帆生物科技集团股份有限公司 2025 年第一季度报告" which translates to "Jianfan Biotechnology Group Co., Ltd. 2025 First Quarter Report." It contains detailed financial data including income statement, balance sheet, cash flow statement, and analysis of financial metrics for the first quarter of 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and management discussion of financial results. It is not a brief announcement or a certification letter but a full financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-15 Chinese
2024年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for the fiscal year 2024 of 健帆生物科技集团股份有限公司. It contains detailed audit opinions, basis for audit opinions, key audit matters, responsibilities of management and auditors, and extensive financial statements including consolidated and company balance sheets, income statements, and cash flow statements. The presence of detailed audit procedures, auditor signatures, and comprehensive financial data confirms this is a standalone audit report rather than a full annual report or an announcement. The document length is substantial (15,000 characters), indicating it is the full report, not just an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2024
2025-04-15 Chinese
2024年度董事会工作报告
Annual Report Classification · 95% confidence The document is titled as the "2024年度董事会工作报告" (2024 Annual Board Work Report) of 健帆生物科技集团股份有限公司. It contains detailed information about the company's operating results, business segments, marketing, R&D, talent development, digital transformation, social responsibility, and governance activities during the 2024 fiscal year. It also includes detailed descriptions of board meetings, committee activities, and shareholder meetings. The document is comprehensive and lengthy (15,000 characters), containing substantive financial data, operational review, and governance information. This matches the characteristics of an Annual Report (10-K) which covers company activity and full financial performance for the year. It is not a short announcement or a proxy statement, nor is it a transcript or a regulatory filing. Therefore, the document should be classified as an Annual Report (10-K). FY 2024
2025-04-15 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.